Know Cancer

forgot password

Study of the Nucleus 24 Auditory Brainstem Implant in Pediatric Non-Neurofibromatosis Type 2

6 Months
17 Years
Open (Enrolling)
Bilateral Hearing Loss for Causes Other Than Tumors

Thank you

Trial Information

Study of the Nucleus 24 Auditory Brainstem Implant in Pediatric Non-Neurofibromatosis Type 2

The goal of this MEEI Auditory Brainstem Implant (ABI) research study is to find new ways to
improve hearing in children who are deaf and cannot receive a cochlear implant. The ABI is
a surgically placed bionic implant that converts sounds into electrical signals that are
directly transmitted to the cochlear nucleus, the first auditory center of the brain. For
many years, ABIs have improved the hearing of patients who are deaf due to brain tumors
associated with a genetic syndrome called Neurofibromatosis Type 2 (NF2). However, a number
of recent studies suggest that deaf patients who do not have NF2 and are not eligible for a
cochlear implant may also benefit from placement of an ABI. These preliminary studies
suggest that these non-NF2 or "nontumor" patients may actually have better outcomes after
ABI surgery than patients suffering from NF2. Children appear to be particularly good
candidates because of their developmental plasticity and in many studies, outcomes are more
favorable in children that adults. Patients who do not have NF2 and are deaf due to
abnormalities in their hearing nerves or inner ears from congenital malformations,
infection, disease, or injury are not cochlear implant candidates and there are no other
options to improve hearing in these cases except for the ABI. Thus, the purpose of our study
is to carefully analyze whether ABI surgery improves the hearing and quality of life of
non-NF2 children based on subjective and objective measures of their hearing before and
after ABI surgery. In particular, we plan to study ABI outcomes in non-NF2 pediatric
patients, characterize the parameters used on their devices, and determine the safety
profile of ABIs in these patients.

Inclusion Criteria:

1. Pre-linguistic hearing loss (birth-5 yrs.; age at ABI 18 months-5yrs) with both:

1. MRI +/- CT evidence of one of the following:

- Cochlear nerve deficiency

- Cochlear aplasia or severe hypoplasia

- Severe inner ear malformation

- Post-meningitis ossification

2. When a cochlea is present or patent with a normally appearing cochlear nerve,
lack of significant benefit from CI despite consistent use (>6 mo.)

- No or limited speech perception ability (limited to pattern perception on
closed set testing materials using the CI)

- Lack of progress in auditory skills development

2. Post-linguistic hearing loss (<18 yrs. of age) with both:

1. Loss or lack of benefit from appropriate CI without the possibility for revision
or contralateral implantation. Examples might include:

- Post-meningitis ossification

- Bilateral temporal bone fractures with cochlear nerve avulsion

- Failed revision CI without benefit

2. Previously developed open set speech perception and auditory-oral language

3. No medical contraindications

4. Willing to receive the appropriate meningitis vaccinations

5. No or limited cognitive/developmental delays which would be expected to interfere
with the child's ability to cooperate in testing and/or programming of the device, in
developing speech and oral language, or which would make an implant and subsequent
emphasis on aural/oral communication not in the child's best interest

6. Strong family support including language proficiency of the parent(s) in the child's
primary mode of communication as well as written and spoken English.

7. Reasonable expectations from parents including a thorough understanding:

- of potential benefits and limitations of ABI

- of parental role in rehabilitation

- that the child may not develop spoken language as a primary communication mode
or even sufficient spoken language to make significant academic progress in an
aural/oral environment

8. Involvement in an educational program that emphasizes development of auditory skills
with or without the use of supplementary visual communication.

9. Able to comply with study requirements including travel to investigation sites and
clinic visits.

10. Informed consent for the procedure from the child's parents.

Exclusion Criteria:

1. Pre- or post-linguistic child currently making significant progress with CI - This
will be considered if a child is progressing along the expected speech reception
hierarchy (SRI-Q) as detailed by Wang et al (50). Even for the very young children
(18 months of age with 6 months of use), nearly all children with a good auditory
signal from their CI will have reached ceiling effects on the IT-MAIS and have
pattern perception beyond chance using the ESP (50). Moreover, there will evidence of
improvement in these metrics over time.

2. MRI evidence of one of the following:

- normal cochlea and cochlear nerves or NF2

- brainstem or cortical anomaly that makes implantation unfeasible

3. Clear surgical reason for poor CI performance that can be remediated with revision CI
or contralateral surgery rather than ABI.

4. Intractable seizures or progressive, deteriorating neurological disorder

5. Unable to participate in behavioral testing and mapping with their CI. If this
appears to be an age effect, ABI will be delayed until we can be assured that the
child will be able to participate, as reliable objective measures of mapping are
currently not available for mapping these devices.

6. Lack of potential for spoken language development. This will be considered the case
when evidence of the following exist:

- Severe psychomotor retardation, autism, cerebral palsy, or developmental delays
beyond speech that would preclude usage of the device and oral educational
development. Autism is a special case where there is the potential for delayed
presentation. When early signs are considered present, we will request a
comprehensive developmental assessment for further evaluation prior to
considering routine evaluation.

7. Unable to tolerate general anesthesia (cardiac, pulmonary, bleeding diathesis, etc.).

8. Need for brainstem irradiation

9. Unrealistic expectations on the part of the subject/family regarding the possible
benefits, risks and limitations that are inherent to the procedure and prosthetic

10. Unwilling to sign the informed consent.

11. Unwilling to make necessary follow-up appointments.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

ABI Complications

Outcome Description:

We will track any major and minor complications peri-operatively and post-operatively in all study participants. Major complications include mortality, cerebellar contusion, facial palsy, meningitis, lower cranial neuropathy, hydrocephalus, pseudomeningocele and CSF leak. Minor complications include transient hydrocephalus, wound seroma, minor infections, balance problems, transient nerve palsies, transient dysphonia or difficulty swallowing, headache, flap problems, and non-auditory side effects. These complications will be tracked through serial clinical exams as well as patient recorded questionnaires to determine the safety profile of ABI surgery.

Outcome Time Frame:

5 years from date of surgery

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

May 2013

Completion Date:

November 2022

Related Keywords:

  • Bilateral Hearing Loss for Causes Other Than Tumors
  • Auditory Brainstem Implant
  • ABI
  • Nucleus 24
  • Deafness
  • Hearing loss
  • Non-tumor
  • Non-NF2
  • Pediatric
  • Hearing Loss
  • Deafness
  • Hearing Loss, Bilateral



Massachusetts Eye and Ear Infirmary Boston, Massachusetts  02114-3096